Chronic graft-versus-host disease develops when donated stem cells attack the patient’s own body. It affects 40 to 50% of stem cell transplant recipients. In most cases three or more organs are involved. For patients who have already failed two lines of treatment, the options until now have been limited and the outcomes often poor.
Australia just approved a new one.
The Therapeutic Goods Administration granted marketing authorization for NIKTIMVO (axatilimab) on May 3, 2026, making Australia the first country to approve the drug since its US FDA approval in August 2024. The approval came through the TGA’s Priority Review pathway, which applies to therapies addressing serious conditions with unmet medical need. Specialised Therapeutics, which holds exclusive rights to commercialize NIKTIMVO in Australia, New Zealand, and Singapore through a 2025 partnership with Incyte (NASDAQ: INCY), will bring the drug to Australian prescribers for patients with chronic GVHD who have failed at least two prior lines of systemic therapy.
The research that made NIKTIMVO possible began in Australia in 2014.
What axatilimab does and why the mechanism matters
NIKTIMVO is a first-in-class colony stimulating factor-1 receptor blocking antibody. CSF-1R is a signaling pathway that drives the inflammatory and fibrotic processes responsible for the multi-organ damage characteristic of chronic GVHD. Scientists at QIMR Berghofer, a Queensland medical research institute, made the initial discovery that identified both the cellular process causing chronic GVHD and the antibody capable of blocking it.
That discovery, made a decade before this approval, represents a genuine contribution to the disease’s biological understanding. Chronic GVHD has historically been treated with immunosuppressive drugs that broadly dampen immune activity. Axatilimab takes a more targeted approach, blocking the specific receptor that drives the macrophage-mediated inflammation and fibrosis destroying affected tissues.
The Phase 2 AGAVE-201 trial, published in the New England Journal of Medicine in 2024, enrolled 241 patients across 121 sites in 16 countries, including Australian sites. The overall response rate at the approved dose was 74%. Sixty percent of patients maintained their response at 12 months. Those are meaningful numbers in a patient population that has already progressed through two prior treatment lines.
The clinical reality for Australian patients
Approximately 600 allogeneic stem cell transplants are performed in Australia each year. Chronic GVHD develops in roughly 40 to 50% of those recipients, typically four to six months after transplant. Almost half of those patients will require at least three different therapies before achieving disease control.
For the subset who progress to third-line treatment and beyond, the disease is often multi-organ, severely symptomatic, and resistant to standard approaches. Skin involvement, muscle weakness, joint stiffness, liver damage, and lung fibrosis can develop simultaneously. The functional decline is significant. Non-relapse mortality, death attributable to chronic GVHD rather than recurrent cancer, is a real risk in this population.
Professor Jeff Szer, a clinical haematologist at Peter MacCallum Cancer Centre and the Royal Melbourne Hospital, framed the approval’s clinical significance plainly: NIKTIMVO provides an important new treatment option for patients who continue to progress on other therapies, experience higher symptom burden, and functional decline.
The reimbursement question
TGA approval authorizes prescribing. It does not mean patients can access the drug without significant out-of-pocket cost. NIKTIMVO is not listed on Australia’s Pharmaceutical Benefits Scheme. Specialised Therapeutics is pursuing PBS listing, which would make the drug accessible at subsidized prices for eligible patients.
The PBS listing process in Australia typically takes 12 to 18 months after marketing approval. Until listing is granted, access depends on institutional funding, compassionate access programs, or private payment. Professor Szer explicitly called on the government and Specialised Therapeutics to determine a reimbursement pathway urgently, recognizing that approval without access is incomplete for patients who need the drug now.
According to the Pharmaceutical Benefits Advisory Committee’s assessment framework, drugs addressing serious conditions with demonstrated clinical benefit over existing therapies are assessed under cost-effectiveness criteria that weigh clinical outcomes against price. The AGAVE-201 data provides the clinical evidence base. The commercial negotiation determines when PBS listing converts TGA approval into real-world access.
Sources
- Pharmaceutical Benefits Advisory Committee — PBS Listing Guidelines
- New England Journal of Medicine — AGAVE-201 Trial Results
- Specialised Therapeutics — Official Website
Editorial disclosure
This article is based on a press release issued by Specialised Therapeutics and has been independently rewritten and editorially expanded. It covers TGA approval of NIKTIMVO (axatilimab) for chronic graft-versus-host disease in Australia. Incyte Corporation trades on NASDAQ under the ticker INCY. NIKTIMVO is not listed on Australia’s Pharmaceutical Benefits Scheme. PBS listing is being pursued separately and is not guaranteed. This article does not constitute medical advice. Market context is sourced from the PBAC and the New England Journal of Medicine. Commentary reflects the author’s own assessment. The information provided on this website is for informational and educational purposes only. Our content is derived strictly from verified online sources to ensure accuracy and objectivity. This analysis does not constitute financial, investment, or professional advice. Readers are encouraged to consult with qualified professionals before making decisions based on this information. For more information, please see our full DISCLAIMER.
